BE with 1 not included in CI -danish twist [RSABE / ABEL]

posted by bjkim97  – Korea / Seoul, 2013-02-06 06:56 (4888 d 14:14 ago) – Posting: # 9969
Views: 6,551

❝ Dear d_labes!



❝ If your study is aimed for the European market no go! The widest acceptance range allowed in the EMA guidance is 69.84% ... 143.19% given that your study is a replicate crossover study and your intra-subject CV of the Reference from that study is >=50%. Note that the widening is only allowed for Cmax.


Why this CV(Intra) is >=50%?
Is this CV(Intra)>=30%?. Is not that widening is more than >=30%?

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,570 registered users;
396 visitors (0 registered, 396 guests [including 25 identified bots]).
Forum time: 22:10 CEST (Europe/Vienna)

Ignorance more frequently begets confidence
than does knowledge.    Charles Darwin

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5